News | Balloon Catheter | May 22, 2017

Abbott Recalls 449,661 Coronary Balloon Catheters

Recall affects three Abbott balloon catheters due to difficulty removing balloon sheath

Abbott recalls its NC Balloon catheters

May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports of injury, and one report of death associated with difficulty removing the protective balloon sheath, resulting in issues with inflating or deflating the balloon. Abbott is recalling products from several identified lots because physicians may experience difficulty in removing the protective balloon sheath. This can result in issues with inflating or deflating the balloon during procedures and may cause serious adverse health consequences including air embolism, thrombosis, myocardial infarction and death.

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Abbott began contacting customers in March who received coronary catheters from the affected lots and is arranging the return and replacement of all remaining products. The total number of distributed units from identified lots potentially affected is 449,661. Global Health Authorities have been notified of the voluntary recall.

The recalled products include:
• Abbott NC Trek RX Coronary Dilatation Catheter

• Abbott NC Traveler Coronary Dilatation Catheter

• Abbott NC Tenku RX PTCA Balloon Catheter

Specific lots of affected product were manufactured between Jan. 1, 2015 – Jan. 2, 2017, and were distributed between Jan. 13, 2015 – March 14, 2017. Click on the specific catheter links above to see which lots were recalled.

Abbott said the specified balloons may exhibit difficulty in removing the protective balloon sheath, which can result in issues with inflating or deflating the balloon. The worldwide frequency of tight sheath removal, inflation and deflation reported events is 0.12 percent, the company said. In one reported case, failure to deflate the balloon necessitated surgery, leading to multiple post-operative complications and death.

Abbott said this recall does not affect patients having successfully undergone cardiac procedures using these devices. 

On March 22, 2017, Abbott sent a Field Safety Notice letter to healthcare providers and risk managers informing them of the device's risks, and corrective actions that would be implemented to ensure ongoing product performance. The letter asked providers and risk managers to immediately stop using the devices from the identified lots and remove or quarantine them. The vendor also said providers could contact Abbott Vascular to obtain a return authorization number to return all affected and unused products to the company.

Abbott also asked providers to acknowledge receipt of the notification by returning the "Effectiveness Check Form" provided by Abbott Vascular by email to: [email protected], or via fax at (951) 914-5951. 

Abbott's coronary dilatation catheters are indicated for use in balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis, coronary artery occlusion in patients with ST-segment elevation myocardial infarction (STEMI), and balloon dilatation of a stent after implantation (2-5 mm balloon models only).

Customers with questions may contact their local Abbott Vascular representative, or contact Abbott's customer service department at (800) 227-9902.

For more information: www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm559603.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init